Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]Product type:GuidanceProgramme:Technology appraisal guidanceExpected publication date: 15 June 2022
Suspected cancer: recognition and referral (NG12)Product type:GuidanceProgramme:NICE guidelineLast updated: 2 October 2023Published: 23 June 2015
Memokath 051 Ureter stent for ureteric obstruction (MTG75)Product type:GuidanceProgramme:Medical technologies guidancePublished: 7 December 2022
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 August 2022
Enfortumab vedotin for previously treated locally advanced or metastatic urothelial cancer (terminated appraisal) (TA797)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 15 June 2022
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy (TA788)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 11 May 2022
Synergo for non-muscle-invasive bladder cancer (MTG61)Product type:GuidanceProgramme:Medical technologies guidancePublished: 30 November 2021
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitable (TA739)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 27 October 2021
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA692)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 28 April 2021
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal) (TA674)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 17 February 2021
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 24 July 2019
Electrically stimulated intravesical chemotherapy for non-muscle-invasive bladder cancer (IPG638)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 30 January 2019
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 19 September 2018
Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (TA530)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 4 July 2018
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (TA525)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 June 2018
Bladder cancer: diagnosis and management (NG2)Product type:GuidanceProgramme:NICE guidelinePublished: 25 February 2015
Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract (TA272)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 23 January 2013
Laparoscopic cystectomy (IPG287)Product type:GuidanceProgramme:Interventional procedures guidancePublished: 25 February 2009
Improving outcomes in urological cancers (CSG2)Product type:GuidanceProgramme:Cancer service guidelinePublished: 19 September 2002
Signatera for detecting molecular residual disease from solid tumour cancers (MIB307)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 October 2022
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)Product type:AdviceProgramme:Medtech innovation briefingPublished: 3 May 2022
URO17 for detecting bladder cancer (MIB250)Product type:AdviceProgramme:Medtech innovation briefingPublished: 4 February 2021
ADXBLADDER for detecting bladder cancer (MIB180)Product type:AdviceProgramme:Medtech innovation briefingPublished: 12 April 2019
Suspected cancer (QS124)Product type:Quality standardLast updated: 5 December 2017Published: 30 June 2016
Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 February 2025
Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 4 June 2025
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID 5080]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer [ID5102]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Electrically-stimulated intravesical chemotherapy for non-muscle invasive bladder cancerStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Bladder EpiCheck for the detection of bladder cancer recurrence (MT706)Status:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
MemoKath Stent InsertionStatus:Topic selectionProgramme:Interventional procedures guidanceExpected publication date: TBC
Durvalumab for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer [ID6168]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Enfortumab vedotin with pembrolizumab for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6301]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Pembrolizumab with chemoradiation for untreated muscle-invasive non-metastatic bladder cancer TS ID 11953Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
URO17 for testing suspected bladder cancerStatus:Topic selectionProgramme:Diagnostics guidanceExpected publication date: TBC
Signatera molecular residual disease assay (MT741)Status:Topic selectionProgramme:Medical technologies guidanceExpected publication date: TBC
Pembrolizumab adjuvant for urothelial carcinoma and/or localised muscle invasive bladder cancer TSID 12021Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Sasanlimab with BCG for treating high-risk non-muscle-invasive bladder cancer with papillary tumours or carcinoma in situ untreated with BCG TSID 12042Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC